Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KLK7 | P49862 | 2/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364083 | 0.96 | SYK (0.57) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL20953714 | 0.89 | SYK (0.60) | MAPTKLK7KLK5SYKKEAP1 | |
| SCHEMBL8838459 | 0.85 | MAPT (0.67) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL29401232 | 0.85 | MAPT (0.67) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL30915257 | 0.85 | MAPT (0.67) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL13767610 | 0.85 | MEN1 (0.48) | MAPT | |
| SCHEMBL31429918 | 0.84 | MAPT (0.66) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL1022850 | 0.84 | MAPT (0.66) | MAPTKLK7KLK5SYKITGB3 | |
| SCHEMBL1134604 | 0.84 | MAPT (0.66) | MAPTKLK7KLK5SYKITGB3 | |
| Bicarbonate SCHEMBL5175781 | 0.84 | MAPT (0.66) | MAPTKLK7KLK5SYKITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440584-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250090696-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2025-03-20 | — | — | US | disclosed |
| US-11951188-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11603371-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2023-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067650-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | MAPT 2173/4885KLK7 2698/4885KLK5 2850/4885 |
| US-12440584-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | MAPT 2173/4885KLK7 2698/4885KLK5 2850/4885 |
| US-11603371-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | MAPT 2173/4885KLK7 2698/4885KLK5 2850/4885 |
| US-20250090696-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | MAPT 2173/4885KLK7 2698/4885KLK5 2850/4885 |
| US-11951188-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | MAPT 2173/4885KLK7 2698/4885KLK5 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.